New PET tracers could sharpen kidney cancer detection
NCT ID NCT07301827
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to see if new PET imaging agents can better detect and stage kidney cancer (renal cell carcinoma). Researchers will use special tracers that target proteins on cancer cells, such as PSMA, CAIX, and CD70, in 66 adults with suspected or confirmed kidney cancer and healthy volunteers. The goal is to improve diagnosis and help guide treatment decisions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who needs extra therapy after kidney cancer surgery?
- Can a Two-Drug combo outsmart advanced cancers?
- Can a rapid drug switch outsmart advanced kidney cancer?
- Can a new nucleotide analogue boost cancer treatment?
- Can a blast of radiation make immunotherapy work better against kidney cancer?
- Can reprogrammed immune cells take on hard-to-treat kidney cancer?